KALA BIO, Inc. (KALA)

Market Cap	40.45M
Revenue (ttm)	n/a
Net Income (ttm)	-38.96M
Shares Out	6.09M
EPS (ttm)	-11.81
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	30,993
Open	6.95
Previous Close	6.84
Day's Range	6.57 - 6.95
52-Week Range	4.21 - 11.20
Beta	-2.04
Analysts	Strong Buy
Price Target	15.00 (+125.9%)
Earnings Date	Mar 28, 2025

About KALA

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company’s product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, I...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 20, 2017
• Employees: 43
• Stock Exchange: NASDAQ
• Ticker Symbol: KALA
• Website: https://www.kalarx.com

Analyst Forecast

According to 2 analysts, the average rating for KALA stock is "Strong Buy." The 12-month stock price forecast is $15.0, which is an increase of 125.90% from the latest price.

Price Target

$15.0

(125.90% upside)

Analyst Consensus: Strong Buy